Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30812814 | 0.85 | AKR1B1 (0.57) | AKR1B1KDM4EGPR17CA2LMNA | |
| SCHEMBL18301609 | 0.85 | AKR1B1 (0.52) | AKR1B1KDM4EGPR17CA2LMNA | |
| SCHEMBL18301625 | 0.85 | AKR1B1 (0.57) | AKR1B1KDM4EGPR17CA2LMNA | |
| SCHEMBL29459948 | 0.84 | AKR1B1 (0.43) | AKR1B1KDM4ECA2LMNASMN1; SMN2 | |
| SCHEMBL909585 | 0.84 | AKR1B1 (0.43) | AKR1B1KDM4ECA2LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1372127 | 0.82 | AKR1B1 (0.42) | AKR1B1KDM4ECA2LMNASMN1; SMN2 | |
| SCHEMBL22031847 | 0.81 | AKR1B1 (0.48) | AKR1B1KDM4ECA2LMNASMN1; SMN2 | |
| SCHEMBL29457633 | 0.81 | AKR1B1 (0.48) | AKR1B1KDM4ECA2LMNASMN1; SMN2 | |
| SCHEMBL19522398 | 0.81 | GPR17 (0.55) | KDM4EGPR17 | |
| SCHEMBL12709973 | 0.80 | TSHR (0.41) | KDM4ESMN1; SMN2MAPTKMT2ACD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| EP-3114715-A1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | Siemens Aktiengesellschaft (DE) | 2017-01-11 | — | — | EP | claimed |
| US-20250185502-A1 | ORGANIC OPTOELECTRONIC COMPONENT, ORGANIC FUNCTIONAL LAYER, AND METHOD FOR PRODUCING AN OPTOELECTRONIC COMPONENT | OSRAM OLED GMBH (DE) | 2025-06-05 | — | — | US | disclosed |
| US-12302747-B2 | Optoelectronic component, organic functional layer, and method for producing an optoelectronic component | OSRAM OLED GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| EP-4193399-B1 | ELECTRONIC DEVICE | MERCK PATENT GMBH (DE) | 2025-01-29 | — | — | EP | disclosed |
| EP-3210248-B2 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2024-04-10 | — | — | EP | disclosed |
| EP-4193399-A2 | ELECTRONIC DEVICE | Merck Patent GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| CN-116194434-A | Electronic device | 默克专利有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-107074797-B | Material for electronic devices | 默克专利有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11038127-B2 | Optoelectronic component, organic functional layer, and method for producing an optoelectronic component | OSRAM OLED GMBH (DE) | 2021-06-15 | — | — | US | disclosed |
| EP-3298639-B1 | FORMULATION CONTAINING AN ORGANIC SEMICONDUCTOR AND A METAL COMPLEX | MERCK PATENT GMBH (DE) | 2021-01-13 | — | — | EP | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-20150162534-A1 | METAL COMPLEXES AS P-TYPE DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | OSRAM OLED GMBH (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150123047-A1 | MAIN GROUP METAL COMPLEXES AS P-DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | OSRAM OLED GMBH (DE) | 2015-05-07 | — | — | US | disclosed |
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-04-30 | — | — | US | disclosed |
| EP-1314725-B1 | SULFONIUM SALT COMPOUND | WAKO PURE CHEM IND LTD (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-6924323-B2 | Sulfonium salt compound | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040033434-A1 | Sulfonium salt compound | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1314725-A1 | SULFONIUM SALT COMPOUND | Wako Pure Chemical Industries, Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | AKR1B1 3456/4885KDM4E 2130/4885GPR17 4058/4885 |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | IMPA1, IMPDH1, IPO5 | AKR1B1 2359/4885KDM4E 1726/4885GPR17 3656/4885 |
| US-20040033434-A1 | Sulfonium salt compound | SPIN1, RER1, SPIN2B | AKR1B1 3105/4885KDM4E 1259/4885GPR17 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.